<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02188251</url>
  </required_header>
  <id_info>
    <org_study_id>14AWHG</org_study_id>
    <nct_id>NCT02188251</nct_id>
  </id_info>
  <brief_title>A Study Investigating the Effects of Activamp on Body Weight, Fat Loss, and Metabolic Markers in Healthy Overweight Participants</brief_title>
  <acronym>14AWHG</acronym>
  <official_title>A Randomized, Double-blind, Placebo Controlled, Parallel Study Investigating the Effects of Activamp on Body Weight, Fat Loss, and Metabolic Markers in Healthy Overweight Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KGK Synergize Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gencor Pacific Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>KGK Synergize Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effects of Activamp, a product containing
      gynostemma pentaphyllum extract, on body weight, fat loss and metabolic markers in healthy
      overweight adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Baseline to week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in calculated BMI</measure>
    <time_frame>baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in calculated percent body fat</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in calculated body fat mass</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in calculated lean body mass</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total body fat percentage</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>As determined by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total fat mass</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>As determined by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in total lean mass</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>As determined by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in percent android fat</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>As determined by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in percent gynoid fat</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>As determined by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in percent trunk and legs fat</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>As determined by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in percent abdominal fat</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>As determined by DXA scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in anthropometric measurements</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>Waist and Hip circumference</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood AMPK activity</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood metabolic parameters</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
    <description>lipid profile, Apo A1, Apo B, FFA, insulin and glucose, HOMA-IR, HbA1c, IGF, HsCrp, TNFalpha and glycerol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood safety parameters</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>CBC, electrolytes, markers of kidney and liver function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in safety vital signs</measure>
    <time_frame>Baseline to week 12</time_frame>
    <description>Blood pressure, heart rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Body Weight</condition>
  <arm_group>
    <arm_group_label>Activamp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules containing 225mg of Activamp (Gynostemma pentaphyllum extract), 1 capsule taken twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 capsule taken twice daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Activamp</intervention_name>
    <arm_group_label>Activamp</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male or female 21-55 years of age

          -  BMI of 25.0 kg/m2 to 29.9 kg/m2 (Â± 1.0kg/m2)

          -  Must have negative urine pregnancy test at screening

          -  Female subject of childbearing potential must agree to use a medically approved method
             of birth control and have a negative urine pregnancy test result.

          -  Subject agrees to maintain their normal level of physical activity throughout the
             study

          -  Weight has been stable for the last 3 months

          -  Subject agrees to comply with study procedures

          -  Healthy as determined by laboratory results, medical history and physical exam

          -  Subject agrees not to participate in structured activity including resistance training
             and aerobic exercise more than 3 times per week

          -  Has given voluntary, written, informed consent to participate in the study

        Exclusion Criteria:

          -  Women who are pregnant, breastfeeding, or planning to become pregnant during the
             course of the trial

          -  Subject who have experienced a greater than 10% variation in body weight in the past 3
             months

          -  History of, or current diagnosis of any major diseases of the cardiovascular, hepatic,
             renal, gastrointestinal, pulmonary or endocrine systems

          -  History of surgery for weight loss (including gastric bypass or lapband)

          -  History of conditions that could interfere with the test product or impede its
             absorption such as gastrointestinal disease (Crohn's disease) or experienced surgery
             (caecum or enterocele surgery)

          -  Subjects diagnosed with Type II Diabetes

          -  Subjects with active cancer (excluding basal cell carcinoma)

          -  Subjects with active eating disorders

          -  Subjects who have undergone anti-psychotic drug therapy within the past 2 months

          -  Use of prescription or over the counter medications known to affect weight within 3
             weeks of randomization or during the study

          -  Use of any supplements, programs, or meal replacement products, other than those
             provided, intended to alter body weight within two weeks of screening or during the
             course of the study

          -  Use of illicit drugs or history of drug or alcohol abuse within the past 6 months

          -  Currently having more than 2 standard alcoholic drinks per day

          -  Participation in a clinical research trial within 30 days prior to randomization

          -  Allergy or sensitivity to test article ingredients

          -  Individuals who are cognitively impaired and/or who are unable to give informed
             consent

          -  Abnormal lab test results or any other medical or psychological condition which in the
             Investigator's opinion may adversely affect the subject's ability to complete the
             study or its measures or which may pose significant risk to the subject
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dale Wilson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>KGK Synergize Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>KGK Synergize Inc.</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2014</study_first_submitted>
  <study_first_submitted_qc>July 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2014</study_first_posted>
  <last_update_submitted>August 11, 2015</last_update_submitted>
  <last_update_submitted_qc>August 11, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Activamp</keyword>
  <keyword>Gynostemma pentaphyllum</keyword>
  <keyword>Body weight</keyword>
  <keyword>Fat Loss</keyword>
  <keyword>Metabolic markers</keyword>
  <keyword>Overweight participants</keyword>
  <keyword>DXA</keyword>
  <keyword>AMPK</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Body Weight</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

